Katalog Plus
Bibliothek der Frankfurt UAS
Bald neuer Katalog: sichern Sie sich schon vorab Ihre persönlichen Merklisten im Nutzerkonto: Anleitung.
Dieses Ergebnis aus BASE kann Gästen nicht angezeigt werden.  Login für vollen Zugriff.

Impact of GLP-1 Receptor Agonist Therapy on Atrial Fibrillation Recurrence After Catheter Ablation in Obese Patients: A Real-World Data Analysis

Title: Impact of GLP-1 Receptor Agonist Therapy on Atrial Fibrillation Recurrence After Catheter Ablation in Obese Patients: A Real-World Data Analysis
Authors: Venier, Sandrine; Defaye, Pascal; Lochon, Lisa; Benali, Rémi; Bisson, Arnaud; Carabelli, Adrien; Diouf, Youssou; Jacon, Peggy; Fauchier, Laurent
Source: Circulation: Arrhythmia and Electrophysiology ; volume 19, issue 1 ; ISSN 1941-3149 1941-3084
Publisher Information: Ovid Technologies (Wolters Kluwer Health)
Publication Year: 2026
Description: BACKGROUND: GLP-1 (glucagon-like peptide-1) receptor agonists (GLP-1RAs), initially developed for glycemic control in type 2 diabetes, have shown cardiometabolic benefits including weight loss, improved endothelial function, and reduced inflammation. Recent data suggest potential anti-arrhythmic effects via modulation of atrial substrate and autonomic tone. Their impact on obese, nondiabetic patients remains underexplored. This study examines whether GLP-1RA use is associated with reduced atrial fibrillation recurrence after catheter ablation in obese patients, using real-world data from a large multicenter database. METHODS: We conducted a retrospective cohort study using the TriNetX research network, which contains de-identified electronic health records from >100 million patients. Adult patients (age ≥18 years) with obesity (body mass index >30 kg/m²) who underwent atrial fibrillation (AF) ablation between January 2015 and January 2025 were eligible. The cohort was divided into GLP-1RA users (n=3350) and nonusers (n=3350), with 1:1 propensity score matching performed across 82 clinical and demographic variables, including age, sex, race, AF subtype, cardiovascular comorbidities, and baseline medications. RESULTS: During a median follow-up of 2 years (interquartile range, 0.8–3.2) AF recurrence was significantly lower in GLP-1RA users versus non users (6.66% versus 7.72%; hazard ratio [HR], 0.82 [95% CI, 0.76–0.88]; P
Document Type: article in journal/newspaper
Language: English
DOI: 10.1161/circep.125.014101
DOI: 10.1161/CIRCEP.125.014101
Availability: https://doi.org/10.1161/circep.125.014101; https://www.ahajournals.org/doi/full/10.1161/CIRCEP.125.014101
Rights: https://creativecommons.org/licenses/by-nc-nd/4.0/
Accession Number: edsbas.22AEB10
Database: BASE